JPAD-Journal of Prevention of Alzheimers Disease

Papers
(The TQCC of JPAD-Journal of Prevention of Alzheimers Disease is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease148
The Epidemiology of Alzheimer’s Disease Modifiable Risk Factors and Prevention83
Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 202180
Aducanumab: Appropriate Use Recommendations55
Lecanemab: Appropriate Use Recommendations50
Aducanumab: Appropriate Use Recommendations Update35
Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (SToMP-AD): A Pilot Clinical Trial24
Current State of Self-Administered Brief Computerized Cognitive Assessments for Detection of Cognitive Disorders in Older Adults: A Systematic Review23
Effects of Folic Acid and Vitamin B12 Supplementation on Cognitive Impairment and Inflammation in Patients with Alzheimer’s Disease: A Randomized, Single-Blinded, Placebo-Controlled Trial22
Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging19
Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer’s Disease Treated with Anti-Amyloid Beta Therapy17
Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer’s Disease14
Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force14
Socioeconomic Status and Risks of Cognitive Impairment and Dementia: A systematic Review and Meta-Analysis of 39 Prospective Studies12
The Japan-Multimodal Intervention Trial for Prevention of Dementia (J-MINT): The Study Protocol for an 18-Month, Multicenter, Randomized, Controlled Trial10
Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer’s Disease10
Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report9
Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer’s and Parkinson’s Patients7
ITEM-LEVEL INVESTIGATION OF PARTICIPANT AND STUDY PARTNER REPORT ON THE COGNITIVE FUNCTION INDEX FROM THE A4 STUDY SCREENING DATA7
Association of Subjective Cognitive Decline with Risk of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of Prospective Longitudinal Studies7
The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report7
ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aß Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan6
Amyloid and APOE Status of Screened Subjects in the Elenbecestat MissionAD Phase 3 Program6
Major Cost Drivers in Assessing the Economic Burden of Alzheimer’s Disease: A Structured, Rapid Review6
Effects of Mindfulness-Based Tai Chi Chuan on Physical Performance and Cognitive Function among Cognitive Frailty Older Adults: A Six-Month Follow-Up of a Randomized Controlled Trial6
The Scottish Brain Health Service Model: Rationale and Scientific Basis for a National Care Pathway of Brain Health Services in Scotland6
Representation of Racial and Ethnic Minority Populations in Dementia Prevention Trials: A Systematic Review6
Programmed Death of Microglia in Alzheimer’s Disease: Autophagy, Ferroptosis, and Pyroptosis6
The Effects of Dual-Task Training on Cognitive and Physical Functions in Older Adults with Cognitive Impairment; A Systematic Review and Meta-Analysis5
Antihypertensive Agents and Incident Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Observational Studies5
Childhood Secondhand Smoke Exposure and Risk of Dementia, Alzheimer’s Disease and Stroke in Adulthood: A Prospective Cohort Study5
Detection Rates of Mild Cognitive Impairment in Primary Care for the United States Medicare Population5
Immunotherapy for Alzheimer’s Disease: Current Scenario and Future Perspectives5
POSTERS 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021, Boston, USA5
Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer’s Disease5
Living Environment, Built Environment and Cognitive Function among Older Chinese Adults: Results from a Cross-Sectional Study5
Aging, Senescence, and Dementia5
Blood Derived Amyloid Biomarkers for Alzheimer’s Disease Prevention5
Geniposidic Acid Confers Neuroprotective Effects in a Mouse Model of Alzheimer’s Disease through Activation of a PI3K/AKT/GAP43 Regulatory Axis4
Effectiveness of Physical Exercise on Alzheimer’s disease. A Systematic Review4
Communicating Personal Risk Profiles of Alzheimer’s Disease to Older Adults: A Pilot Trial4
Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: The EU/US CTAD Task Force4
Aducanumab Trials EMERGE But Don’t ENGAGE4
‘Time Saved’ As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings4
Sensitivity of the Preclinical Alzheimer’s Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer’s Disease -Atabece4
Tauroursodeoxycholic Acid Attenuates Diet-Induced and Age-Related Peripheral Endoplasmic Reticulum Stress and Cerebral Amyloid Pathology in a Mouse Model of Alzheimer’s Disease4
Digital Screening for Cognitive Impairment – A Proof of Concept Study4
Cognitive Digital Biomarkers from Automated Transcription of Spoken Language4
Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats4
Effects of Non-Invasive Brain Stimulation on Alzheimer’s Disease4
Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer’s Disease4
Elevated Blood Homocysteine and Risk of Alzheimer’s Dementia: An Updated Systematic Review and Meta-Analysis Based on Prospective Studies4
Association of a MIND Diet with Brain Structure and Dementia in a French Population4
Environmental Distractions during Unsupervised Remote Digital Cognitive Assessment4
Sex Moderates the Association between Frailty and Mild Behavioral Impairment4
The Effect of Multidomain Interventions on Global Cognition, Symptoms of Depression and Apathy – A Pooled Analysis of Two Randomized Controlled Trials3
Burden of Illness in People with Alzheimer’s Disease: A Systematic Review of Epidemiology, Comorbidities and Mortality3
Early-Onset Subgroup of Type 2 Diabetes and Risk of Dementia, Alzheimer’s disease and Stroke: A Cohort Study3
Disease Burden and Attributable Risk Factors of Alzheimer’s Disease and Dementia in China from 1990 to 20193
Aducanumab: Appropriate Use Recommendations3
Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects3
Protocol for the Brain Health Support Program Study of the Canadian Therapeutic Platform Trial for Multidomain Interventions to Prevent Dementia (CAN-THUMBS UP): A Prospective 12-Month Intervention St3
The Role of Thyroid Dysfunction in Alzheimer’s Disease: A Systematic Review and Meta-Analysis3
Platform Trials to Expedite Drug Development in Alzheimer’s Disease: A Report from the EU/US CTAD Task Force3
The ‘Aducanumab Story’: Will the Last Chapter Spell the End of the ‘Amyloid Hypothesis’ or Mark a New Beginning?3
Everyday Functioning and Entorhinal and Inferior Temporal Tau Burden in Cognitively Normal Older Adults3
What Matters to Patients with Alzheimer’s Disease and Their Care Partners? Implications for Understanding the Value of Future Interventions3
Decreased Gray–White Matter Contrast of [11C]-PiB Uptake in Cognitively Unimpaired Subjects with Severe Obstructive Sleep Apnea3
Editorial: What Are the Remaining Challenges before Blood-Based Biomarkers for Alzheimer’s Disease Can Be Used in Clinical Practice?3
The Association between Peanut and Peanut Butter Consumption and Cognitive Function among Community-Dwelling Older Adults3
Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective - Highlights From The Clinical Trials on Alzheimer’s Disease conference (CTAD)3
Multimodal Preventive Trial for Alzheimer’s Disease: MIND-ADmini Pilot Trial Study Design and Progress3
Recruitment of Older African Americans in Alzheimer’s Disease Clinical Trials Using a Community Education Approach3
Salivary Alpha-Amylase Activity and Mild Cognitive Impairment among Japanese Older Adults: The Toon Health Study3
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force3
New Hope for Alzheimer’s Disease2
Associations of Stages of Objective Memory Impairment with Cerebrospinal Fluid and Neuroimaging Biomarkers of Alzheimer’s Disease2
Clusters of Dementia Literacy: Implications from a Survey of Older Adults2
Editorial: Accelerating Innovations for Enhanced Brain Health. Can Artificial Intelligence Advance New Pathways for Drug Discovery for Alzheimer’s and other Neurodegenerative Disorders?2
Are Population-Level Approaches to Dementia Risk Reduction Under-Researched? A Rapid Review of the Dementia Prevention Literature2
Low Amino Acid Score of Breakfast is Associated with the Incidence of Cognitive Impairment in Older Japanese Adults: A Community-Based Longitudinal Study2
Tau Pathologies Mediate the Associations of Vascular Risk Burden with Cognitive Impairments in Non-demented Elders: The CABLE Study2
Study Protocol of a Comprehensive Activity Promotion2
Adult Renal Dysfunction and Risk of Dementia or Cognitive Decline: Brain-Kidney Axis Hypothesis Based on a Systematic Review and Meta-Analysis2
Environmental Enrichment in Murine Models and Its Translation to Human Factors Improving Conditions in Alzheimer Disease2
In Vivo Detection of Changes Related to Cortical Columnar Organization and Neuroinflammation Across the AD Continuum2
POSTERS - 15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USA2
Change on Clinical Trial Outcome Assessments: The Search for Meaningfulness2
Determinants of Medical Direct Costs of Care among Patients of a Memory Center2
Mechanisms Underlying Non-Pharmacological Dementia Prevention Strategies: A Translational Perspective2
Chinese Preclinical Alzheimer’s Disease Study (C-PAS): Design and Challenge from PET Acceptance2
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab2
Clinical Research Investigating Alzheimer’s Disease in China: Current Status and Future Perspectives Toward Prevention2
Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer’s Disease: An Overview of Tests for Clinical Practice in the United States and Europe2
Pharmacological Inventions for Alzheimer Treatment in the United States of America: A Revision Patent from 2010 – 20202
Evidence-Based Tools for Dietary Assessments in Nutrition Epidemiology Studies for Dementia Prevention2
Prediction of Cognitive Decline for Enrichment of Alzheimer’s Disease Clinical Trials2
SYMPOSIA 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021, Boston, USA2
SYMPOSIA - 15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USA2
0.030949115753174